Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study - Tabernero, J; Hoff, PM; Shen, L (Lancet Oncol, 2018)
et al.